| US 7,476,672 B2 | ||
| Acetylenic compounds useful in treating inflammatory disorders | ||
| Scott Beers, Flemington, N.J. (US); Elizabeth A. Malloy, Easton, Pa. (US); and Michael P. Wachter, Bloomsbury, N.J. (US) | ||
| Assigned to Janssen Pharmaceutica N.V., Beerse (Belgium) | ||
| Filed on Jan. 10, 2006, as Appl. No. 11/328,929. | ||
| Application 11/328929 is a division of application No. 10/626155, filed on Jul. 24, 2003, granted, now 7,022,703. | ||
| Claims priority of provisional application 60/356697, filed on Jul. 24, 2002. | ||
| Prior Publication US 2006/0111352 A1, May 25, 2006 | ||
| Int. Cl. A61K 31/5375 (2006.01); C07D 265/30 (2006.01) | ||
| U.S. Cl. 514—237.8 [544/106; 544/162; 546/184; 548/566; 564/305; 514/231.2] | 2 Claims |
1. A compound of Formula (Ib):
 R5b is hydrogen, (C1-10)alkanyl-R7b or phenyl;
R6b is hydrogen or (C1-4)alkanyl-R7b;
R7b is hydrogen, OC(O)—Ra2, N(C1-4alkanyl)2 or Ra2;
Ra2 is pyrrolidinyl-(R12b)q, piperidinyl-(R12b)q, morpholinyl-(R12b)q or phenyl;
(R12b)q is hydrogen or (C1-4)alkanyl;
R2b is hydrogen or (C1-4)alkanyl-R7b;
R3b and R4b are independently hydrogen, (C1-4)alkanyl-R7b, chlorine or fluorine; and,
q is 1; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
|